✨
AI Summary
- Kite Pharma's Will Junker addresses challenges in manufacturing capacity planning for cell therapies.
- Key considerations include partnering with CDMOs and prioritizing inventory over speed.
- Understanding vector manufacturing is crucial for ensuring continuous and secure supply.